Literature DB >> 9863231

[Effect of matrine on mouse hepatitis and tumor necrosis factor production induced by Propionibacterium acnes/lipopolysaccharides].

Z L Hu1, J P Zhang, M B Wan, X B Yu, W Lin, D H Qian.   

Abstract

The effect of matrine (Mat) on lipopolysaccharides (LPS)-induced fatal hepatitis and tumor necrosis factor (TNF) production in Propionibacterium acnes (PA)-primed mice were studied. Mice were injected i.p. LPS (10 micrograms/mouse) 7 d after i.p. PA (0.5 ml/mouse) to induce fatal hepatitis. After i.p. LPS, serum TNF activity rose to 1657 +/- 406 kU.L-1 at 1.5 h and ALT activity increased up to 1,496 +/- 890 U.L-1 at 5 h. Six of 8 mice died within 5 h and the massive hemorrhagic necrosis of the liver was observed in all mice. Administration of Mat (10, 50 mg.kg-1, i.p., bid x 3 d) before the LPS injection markedly reduced the elevation of serum TNF and ALT activity in a dose-dependent manner, and diminished the mortality induced by LPS. Liver congestion and necrosis induced by LPS in PA-primed mice were ameliorated markedly by Mat pretreatment. Mat (62.5-250 mg.L-1) inhibited LPS-induced TNF release from PA-primed mouse peritoneal macrophage in vitro in a concentration-dependent manner. These results seggest that Mat protected PA-primed mice from the development of fatal hepatitis induced by LPS due to inhibition of TNF production.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9863231

Source DB:  PubMed          Journal:  Yao Xue Xue Bao        ISSN: 0513-4870


  2 in total

1.  Anti-HBV effect of liposome-encapsulated matrine in vitro and in vivo.

Authors:  Chang-Qing Li; Yu-Tong Zhu; Feng-Xue Zhang; Lin-Chun Fu; Xiao-Hui Li; Yi Cheng; Xiang-Yang Li
Journal:  World J Gastroenterol       Date:  2005-01-21       Impact factor: 5.742

2.  Matrine Inhibits Infiltration of the Inflammatory Gr1(hi) Monocyte Subset in Injured Mouse Liver through Inhibition of Monocyte Chemoattractant Protein-1.

Authors:  Duo Shi; Jinjin Zhang; Lei Qiu; Jianzhong Li; Zhenlin Hu; Junping Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2013-08-22       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.